

Enfortumab vedotin EV-201 - Cohort 2

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Serious and disabling adverse effects



Other adjustments



Enfortumab vedotin EV-201 - Cohort 2

FINAL SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Genitourinary Cancers
 Therapeutic Indication: Patients with locally advanced or metastatic UC who are ineligible for cisplatin-containing ChT and have previously received ≥1 prior lines of therapy
 Experimental Arm: Enfortumab vedotin
 Control Arm: Single arm (Phase II)



